Roche v. Promega PCR Taq patent validity trial will examine Cetus' conduct in obtaining patent.
This article was originally published in The Gray Sheet
Executive Summary
ROCHE V. PROMEGA TRIAL ON PCR TAQ ENZYME PATENT VALIDITY will seek to determine if Cetus, from which Roche acquired the technology, procured a Taq polymerase patent by "inequitable conduct." "Efficiency will best be served in this case by proceeding to trial as soon as possible on the issue of Cetus' intent to mislead [the Patent Trade Office]," Northern California U.S. District Court Judge Vaughn R. Walxer ruled in an Aug. 9 order. Walxer set a case management conference for Sept. 13, at which time a trial date will be set.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.